|
1
|
Chan RJ, Cooper T, Kratz CP, Weiss B and
Loh ML: Juvenile myelomonocytic leukemia: A report from the 2nd
International JMML Symposium. Leuk Res. 33:355–362. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Niemeyer CM and Kratz CP: Paediatric
myelodysplastic syndromes and juvenile myelomonocytic leukaemia:
Molecular classification and treatment options. Br J Haematol.
140:610–624. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Niemeyer CM, Arico M, Basso G, Biondi A,
Rajnoldi Cantu A, Creutzig U, Haas O, Harbott J, Hasle H, Kerndrup
G, et al: Chronic myelomonocytic leukemia in childhood: A
retrospective analysis of 110 cases. European working group on
myelodysplastic syndromes in childhood (EWOG-MDS). Blood.
89:3534–3543. 1997.PubMed/NCBI
|
|
4
|
Bergstraesser E, Hasle H, Rogge T, Fischer
A, Zimmermann M, Noellke P and Niemeyer CM: Non-hematopoietic stem
cell transplantation treatment of juvenile myelomonocytic leukemia:
A retrospective analysis and definition of response criteria.
Pediatr Blood Cancer. 49:629–633. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dvorak CC and Loh ML: Juvenile
myelomonocytic leukemia: Molecular pathogenesis informs current
approaches to therapy and hematopoietic cell transplantation. Front
Pediatr. 2:252014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Locatelli F, Nollke P, Zecca M, Korthof E,
Lanino E, Peters C, Pession A, Kabisch H, Uderzo C, Bonfim CS, et
al: Hematopoietic stem cell transplantation (HSCT) in children with
juvenile myelomonocytic leukemia (JMML): Results of the
EWOGMDS/EBMT trial. Blood. 105:410–419. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Locatelli F and Niemeyer CM: How I treat
juvenile myelomonocytic leukemia. Blood. 125:1083–1090. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang PI and Marcotte EM: It's the machine
that matters: Predicting gene function and phenotype from protein
networks. J Proteomics. 73:2277–2289. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hedges SB: The origin and evolution of
model organisms. Nat Rev Genet. 3:838–849. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Helsmoortel HH: Gene expression profiling
of 44 JMML patients and 7 healthy donors (discovery cohort). Homo
sapiens. Dec 23–2015.
|
|
11
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: Affy-analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bolstad BM, Irizarry RA, Astrand M and
Speed TP: A comparison of normalization methods for high density
oligonucleotide array data based on variance and bias.
Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Irizarry RA, Hobbs B, Collin F,
Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smyth GK: Limma: Linear models for
microarray data, in Bioinformatics and computational biology
solutions using R and Bioconductor. Springer. 397–420. 2005.
|
|
15
|
Liu H, Xu R, Liu X, Sun R and Wang Q:
Bioinformatics analysis of gene expression in
peripheralbloodmononuclearcells from children with type 1 diabetes
in 3 periods. Exp Clin Endocrinol Diabetes. 122:477–483. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
da Huang W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2008. View Article : Google Scholar
|
|
17
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene Ontology: Tool for the unification of biology. Nat
Genet. 25:25–29. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bindea G, Mlecnik B, Hackl H, Charoentong
P, Tosolini M, Kirilovsky A, Fridman WH, Pagès F, Trajanoski Z and
Galon J: ClueGO: A Cytoscape plug-in to decipher functionally
grouped gene ontology and pathway annotation networks.
Bioinformatics. 25:1091–1093. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bandettini WP, Kellman P, Mancini C,
Booker OJ, Vasu S, Leung SW, Wilson JR, Shanbhag SM, Chen MY and
Arai AE: MultiContrast Delayed Enhancement (MCODE) improves
detection of subendocardial myocardial infarction by late
gadolinium enhancement cardiovascular magnetic resonance: A
clinical validation study. J Cardiovasc Magn Reson. 14:832012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lamb J, Crawford ED, Peck D, Modell JW,
Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et
al: The Connectivity Map: Using gene-expression signatures to
connect small molecules, genes, and disease. Science.
313:1929–1935. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lamb J: The connectivity map: A new tool
for biomedical research. Nat Rev Cancer. 7:54–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang B, Kirov S and Snoddy J: WebGestalt:
An integrated system for exploring gene sets in various biological
contexts. Nucleic Acids Res. 33:W741–W748. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang TY, Dvorak CC and Loh ML: Bedside to
bench in juvenile myelomonocytic leukemia: Insights into
leukemogenesis from a rare pediatric leukemia. Blood.
124:2487–2497. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sakashita K, Kato I, Daifu T, Saida S,
Hiramatsu H, Nishinaka Y, Ebihara Y, Ma F, Matsuda K, Saito S, et
al: In vitro expansion of CD34+CD38− cells
under stimulation with hematopoietic growth factors on AGM-S3 cells
in juvenile myelomonocytic leukemia. Leukemia. 29:606–614. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gualtieri RJ, Castleberry RP, Gibbons J,
Miller DM, Berkow RL, Parmley RT and Banks J: Cell culture studies
and oncogene expression in juvenile chronic myelogenous leukemia.
Exp Hematol. 16:613–619. 1988.PubMed/NCBI
|
|
29
|
Gandre-Babbe S, Paluru P, Aribeana C, Chou
ST, Bresolin S, Lu L, Sullivan SK, Tasian SK, Weng J, Favre H, et
al: Patient-derived induced pluripotent stem cells recapitulate
hematopoietic abnormalities of juvenile myelomonocytic leukemia.
Blood. 121:4925–4929. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hadland BK, Huppert SS, Kanungo J, Xue Y,
Jiang R, Gridley T, Conlon RA, Cheng AM, Kopan R and Longmore GD: A
requirement for Notch1 distinguishes 2 phases of definitive
hematopoiesis during development. Blood. 104:3097–3105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kobayashi M, Shelley WC, Seo W, Vemula S,
Lin Y, Liu Y, Kapur R, Taniuchi I and Yoshimoto M: Functional B-1
progenitor cells are present in the hematopoietic stem
cell-deficient embryo and depend on Cbfβ for their development.
Proc Natl Acad Sci USA. 111:12151–12156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin Y, Yoder MC and Yoshimoto M: Lymphoid
progenitor emergence in the murine embryo and yolk sac precedes
stem cell detection. Stem Cells Dev. 23:1168–1177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoshimoto M, Montecino-Rodriguez E,
Ferkowicz MJ, Porayette P, Shelley WC, Conway SJ, Dorshkind K and
Yoder MC: Embryonic day 9 yolk sac and intra-embryonic hemogenic
endothelium independently generate a B-1 and marginal zone
progenitor lacking B-2 potential. Proc Natl Acad Sci USA.
108:1468–1473. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yoshimoto M, Porayette P, Glosson NL,
Conway SJ, Carlesso N, Cardoso AA, Kaplan MH and Yoder MC:
Autonomous murine T-cell progenitor production in the
extra-embryonic yolk sac before HSC emergence. Blood.
119:5706–5714. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mastrangelo MJ, Maguire HC Jr, Eisenlohr
LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ and Lattime EC:
Intratumoral recombinant gm-csf-encoding virus as gene therapy in
patients with cutaneous melanoma. Cancer Gene Ther. 6:409–422.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McNeel DG, Chen YH, Gulley JL, Dwyer AJ,
Madan RA, Carducci MA and DiPaola RS: Randomized phase II trial of
docetaxel with or without PSA-TRICOM vaccine in patients with
castrate-resistant metastatic prostate cancer: A trial of the
ECOG-ACRIN cancer research group (E1809). Hum Vaccin Immunother.
11:2469–2474. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oudard S, Rixe O, Beuselinck B, Linassier
C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T,
Lefrere-Belda MA, et al: A phase II study of the cancer vaccine
TG4010 alone and in combination with cytokines in patients with
metastatic renal clear-cell carcinoma: Clinical and immunological
findings. Cancer Immunol Immunother. 60:261–271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ottolino-Perry K, Acuna SA, Angarita FA,
Sellers C, Zerhouni S, Tang N and McCart JA: Oncolytic vaccinia
virus synergizes with irinotecan in colorectal cancer. Mol. Oncol.
9:1539–1552. 2015.
|
|
39
|
Quoix E, Lena H, Losonczy G, Forget F,
Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A,
Kazarnowicz A, et al: TG4010 immunotherapy and first-line
chemotherapy for advanced non-small-cell lung cancer (time):
Results from the phase 2b part of a randomised, double-blind,
placebo-controlled, phase 2B/3 trial. Lancet Oncol. 17:212–223.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Foy SP, Sennino B, dela Cruz T, Cote JJ,
Gordon EJ, Kemp F, Xavier V, Franzusoff A, Rountree RB and Mandl
SJ: Poxvirus-based active immunotherapy with PD-1 and LAG-3 dual
immune checkpoint inhibition overcomes compensatory immune
regulation, yielding complete tumor regression in mice. PLoS One.
11:e01500842016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Foy SP, Mandl SJ, dela Cruz T, Cote JJ,
Gordon EJ, Trent E, Delcayre A, Breitmeyer J, Franzusoff A and
Rountree RB: Poxvirus-based active immunotherapy synergizes with
CTLA-4 blockade to increase survival in a murine tumor model by
improving the magnitude and quality of cytotoxic T cells. Cancer
Immunol Immunother. 65:537–549. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cappuccini F, Stribbling S, Pollock E,
Hill AV and Redchenko I: Immunogenicity and efficacy of the novel
cancer vaccine based on simian adenovirus and MVA vectors alone and
in combination with PD-1 mAb in a mouse model of prostate cancer.
Cancer Immunol Immunother. 65:701–713. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dimberg A: Chemokines in angiogenesis.
Curr Top Microbiol Immunol. 341:59–80. 2010.PubMed/NCBI
|
|
44
|
Speyer CL and Ward PA: Role of endothelial
chemokines and their receptors during inflammation. J Invest Surg.
24:18–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ben-Baruch A: The multifaceted roles of
chemokines in malignancy. Cancer Metastasis Rev. 25:357–371. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Luther SA and Cyster JG: Chemokines as
regulators of T cell differentiation. Nat Immunol. 2:102–107. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cancer Genome Atlas Research Network, .
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome
atlas pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
International Cancer Genome Consortium, .
Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan
MK, Calvo F, Eerola I, Gerhard DS, et al: International network of
cancer genome projects. Nature. 464:993–998. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Braun S, Vogl FD, Naume B, Janni W,
Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G,
et al: A pooled analysis of bone marrow micrometastasis in breast
cancer. N Engl J Med. 353:793–802. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Janni W, Vogl FD, Wiedswang G, Synnestvedt
M, Fehm T, Juckstock J, Borgen E, Rack B, Braun S, Sommer H, et al:
Persistence of disseminated tumor cells in the bone marrow of
breast cancer patients predicts increased risk for relapse-a
European pooled analysis. Clin Cancer Res. 17:2967–2976. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Budowle B, Allard MW, Wilson MR and
Chakraborty R: Forensics and mitochondrial DNA: Applications,
debates, and foundations. Ann Rev Genom Hum Genet. 4:119–141. 2003.
View Article : Google Scholar
|
|
54
|
International HapMap Consortium, . Frazer
KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW,
Boudreau A, Hardenbol P, Leal SM, et al: A second generation human
haplotype map of over 3.1 million SNPs. Nature. 449:851–861. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Cheng X, Chen G and Rodriguez WR:
Micro-and nanotechnology for viral detection. Anal Bioanal Chem.
393:487–501. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Pinkel D, Segraves R, Sudar D, Clark S,
Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, et al: High
resolution analysis of DNA copy number variation using comparative
genomic hybridization to microarrays. Nat Genet. 20:207–211. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sozzi G, Conte D, Mariani L, Lo Vullo S,
Roz L, Lombardo C, Pierotti MA and Tavecchio L: Analysis of
circulating tumor DNA in plasma at diagnosis and during follow-up
of lung cancer patients. Cancer Res. 61:4675–4678. 2001.PubMed/NCBI
|
|
58
|
Bhowmick NA, Neilson EG and Moses HL:
2004. Stromal fibroblasts in cancer initiation and progression.
Nature. 432:332–337. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sternlicht MD, Lochter A, Sympson CJ, Huey
B, Rougier JP, Gray JW, Pinkel D, Bissell MJ and Werb Z: The
stromal proteinase MMP3/stromelysin-1 promotes mammary
carcinogenesis. Cell. 98:137–146. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Paszek MJ, Zahir N, Johnson KR, Lakins JN,
Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M,
Boettiger D, et al: Tensional homeostasis and the malignant
phenotype. Cancer Cell. 8:241–254. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Erler JT, Bennewith KL, Nicolau M,
Dornhöfer N, Kong C, Le QT, Chi JT, Jeffrey SS and Giaccia AJ:
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature.
440:1222–1226. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Levental KR, Yu H, Kass L, Lakins JN,
Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, et
al: Matrix crosslinking forces tumor progression by enhancing
integrin signaling. Cell 139. 1–906. 2009.
|
|
63
|
Hynes RO: The extracellular matrix: Not
just pretty fibrils. Science. 326:1216–1219. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wiseman BS, Sternlicht MD, Lund LR,
Alexander CM, Mott J, Bissell MJ, Soloway P, Itohara S and Werb Z:
Site-specific inductive and inhibitory activities of MMP-2 and
MMP-3 orchestrate mammary gland branching morphogenesis. J Cell
Biol. 162:1123–1133. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Stickens D, Behonick DJ, Ortega N, Heyer
B, Hartenstein B, Yu Y, Fosang AJ, Schorpp-Kistner M, Angel P and
Werb Z: Altered endochondral bone development in matrix
metalloproteinase 13-deficient mice. Development. 131:5883–5895.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Rebustini IT, Myers C, Lassiter KS, Surmak
A, Szabova L, Holmbeck K, Pedchenko V, Hudson BG and Hoffman MP:
MT2-MMP-dependent release of collagen IV NC1 domains regulates
submandibular gland branching morphogenesis. Dev Cell. 17:482–493.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lu P, Takai K, Weaver VM and Werb Z:
Extracellular matrix degradation and remodeling in development and
disease. Cold Spring Harb Perspect Biol. 3:a0050582011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Cox TR and Erler JT: Remodeling and
homeostasis of the extracellular matrix: Implications for fibrotic
diseases and cancer. Dis Model Mech. 4:165–178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kitamura T, Qian BZ and Pollard JW: Immune
cell promotion of metastasis. Nat Rev Immunol. 15:73–86. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
DeNardo DG and Coussens LM: Inflammation
and breast cancer. Balancing immune response: Crosstalk between
adaptive and innate immune cells during breast cancer progression.
Breast Cancer Res. 9:2122007. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hatzoglou A, Ouafik L, Bakogeorgou E,
Thermos K and Castanas E: Morphine cross-reacts with somatostatin
receptor SSTR2 in the T47D human breast cancer cell line and
decreases cell growth. Cancer Res. 55:5632–5636. 1995.PubMed/NCBI
|
|
73
|
Rasmussen M, Zhu W, Tønnesen J, Cadet P,
Tønnesen E and Stefano GB: Effects of morphine on tumor growth.
Neuro Endocrinol Lett. 23:193–198. 2002.PubMed/NCBI
|
|
74
|
Mayer TU, Kapoor TM, Haggarty SJ, King RW,
Schreiber SL and Mitchison TJ: Small molecule inhibitor of mitotic
spindle bipolarity identified in a phenotype-based screen. Science.
286:971–974. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Crews CM and Mohan R: Small-molecule
inhibitors of the cell cycle. Curr Opin Chem Biol. 4:47–53. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Liu X, Gong H and Huang K: Oncogenic role
of kinesin proteins and targeting kinesin therapy. Cancer Sci.
104:651–656. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kapoor TM, Mayer TU, Coughlin ML and
Mitchison TJ: Probing spindle assembly mechanisms with monastrol, a
small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol.
150:975–988. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
DeBonis S, Simorre JP, Crevel I, Lebeau L,
Skoufias DA, Blangy A, Ebel C, Gans P, Cross R, Hackney DD, et al:
Interaction of the mitotic inhibitor monastrol with human kinesin
Eg5. Biochemistry. 42:338–349. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Cochran JC and Gilbert SP: ATPase
mechanism of Eg5 in the absence of microtubules: Insight into
microtubule activation and allosteric inhibition by monastrol.
Biochemistry. 44:16633–16648. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Haque SA, Hasaka TP, Brooks AD, Lobanov PV
and Baas PW: Monastrol, a prototype anti-cancer drug that inhibits
a mitotic kinesin, induces rapid bursts of axonal outgrowth from
cultured postmitotic neurons. Cell Motil Cytoskeleton. 58:10–16.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Maliga Z, Kapoor TM and Mitchison TJ:
Evidence that monastrol is an allosteric inhibitor of the mitotic
kinesin Eg5. Chem Biol. 9:989–996. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Müller C, Gross D, Sarli V, Gartner M,
Giannis A, Bernhardt G and Buschauer A: Inhibitors of kinesin Eg5:
Antiproliferative activity of monastrol analogues against human
glioblastoma cells. Cancer Chemother Pharmacol. 59:157–164. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Cascinu S, Bichisao E, Amadori D,
Silingardi V, Giordani P, Sansoni E, Luppi G, Catalano V,
Agostinelli R and Catalano G: High-dose loperamide in the treatment
of 5-fluorouracil-induced diarrhea in colorectal cancer patients.
Support Care Cancer. 8:65–67. 2000.PubMed/NCBI
|
|
84
|
Vail DM: Supporting the veterinary cancer
patient on chemotherapy: Neutropenia and gastrointestinal toxicity.
Top Companion Anim Med. 24:122–129. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Gong XW, Xu YH, Chen XL and Wang YX:
Loperamide, an antidiarrhea drug, has antitumor activity by
inducing cell apoptosis. Pharmacol Res. 65:372–378. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Ohman R and Axelsson R: Relationship
between prolactin response and antipsychotic effect of thioridazine
in psychiatric-patients. Eur J Clin Pharmacol. 14:111–116. 1978.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Realmuto GM, Erickson WD, Yellin AM,
Hopwood JH and Greenberg LM: Clinical comparison of thiothixene and
thioridazine in schizophrenic adolescents. Am J Psychiatry.
141:440–442. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
van Soolingen D, Hernandez-Pando R, Orozco
H, Aguilar D, Magis-Escurra C, Amaral L, van Ingen J and Boeree MJ:
The antipsychotic thioridazine shows promising therapeutic activity
in a mouse model of multidrug-resistant tuberculosis. PLoS One.
5:e126402010. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Thorsing M, Klitgaard JK, Atilano ML, Skov
MN, Kolmos HJ, Filipe SR and Kallipolitis BH: Thioridazine induces
major changes in global gene expression and cell wall composition
in methicillin-resistant Staphylococcus aureus USA300. PLoS One.
8:e645182013. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Byun HJ, Lee JH, Kim BR, Kang S, Dong SM,
Park MS, Lee SH, Park SH and Rho SB: Anti-angiogenic effects of
thioridazine involving the FAK-mTOR pathway. Microvasc Res.
84:227–234. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Park MS, Dong SM, Kim BR, Seo SH, Kang S,
Lee EJ, Lee SH and Rho SB: Thioridazine inhibits angiogenesis and
tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian
cancer xenografts. Oncotarget. 5:4929–4934. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Kang S, Dong SM, Kim BR, Park MS, Trink B,
Byun HJ and Rho SB: Thioridazine induces apoptosis by targeting the
PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells.
Apoptosis. 17:989–997. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Csonka Á, Spengler G, Martins A, Ocsovszki
I, Christensen JB, Hendricks O, Kristiansen JE, Amaral L and Molnar
J: Effect of thioridazine stereoisomers on the drug accumulation of
mouse lymphoma and human prostate cancer cell lines in vitro. In
Vivo. 27:815–820. 2013.PubMed/NCBI
|
|
94
|
Mu J, Xu H, Yang Y, Huang W, Xiao J, Li M,
Tan Z, Ding Q, Zhang L, Lu J, et al: Thioridazine, an antipsychotic
drug, elicits potent antitumor effects in gastric cancer. Oncol
Rep. 31:2107–2114. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Nagel D, Spranger S, Vincendeau M, Grau M,
Raffegerst S, Kloo B, Hlahla D, Neuenschwander M, von Kries Peter
J, Hadian K, et al: Pharmacologic inhibition of MALT1 protease by
phenothiazines as a therapeutic approach for the treatment of
aggressive ABC-DLBCL. Cancer Cell. 22:825–837. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Sachlos E, Risueño RM, Laronde S,
Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn
A, Graham M, et al: Identification of drugs including a dopamine
receptor antagonist that selectively target cancer stem cells.
Cell. 149:1284–1297. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Ke XY, Lin Ng VW, Gao SJ, Tong YW, Hedrick
JL and Yang YY: Co-delivery of thioridazine and doxorubicin using
polymeric micelles for targeting both cancer cells and cancer stem
cells. Biomaterials. 35:1096–1108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Nudelman A, Ruse M, Aviram A, Rabizadeh E,
Shaklai M, Zimrah Y and Rephaeli A: Novel anticancer prodrugs of
butyric acid. 2. J Med Chem. 35:687–694. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Wu CH, Jeng JH, Wang YJ, Tseng CJ, Liang
YC, Chen CH, Lee HM, Lin JK, Lin CH, Lin SY, et al: Antitumor
effects of miconazole on human colon carcinoma xenografts in nude
mice through induction of apoptosis and G0/G1 cell cycle arrest.
Toxicol Appl Pharmacol. 180:22–35. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Lewinska A, Adamczyk-Grochala J,
Kwasniewicz E, Deregowska A and Wnuk M: Ursolic acid-mediated
changes in glycolytic pathway promote cytotoxic autophagy and
apoptosis in phenotypically different breast cancer cells.
Apoptosis. 22:800–815. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Jiao Y, Hannafon BN, Zhang RR, Fung KM and
Ding WQ: Docosahexaenoic acid and disulfiram act in concert to kill
cancer cells: A mutual enhancement of their anticancer actions.
Oncotarget. 8:17908–17920. 2017. View Article : Google Scholar : PubMed/NCBI
|
